US 11,701,338 B2
Use of gTso thal in manufacturing medicament for promotion of MS-275 to cross blood-brain barrier
Xiaohui Zhao, Xining (CN); Ting Zhang, Xining (CN); Huilan Yue, Xining (CN); Jihong Tao, Xining (CN); Wenjing Jia, Xining (CN); Guoying Zhou, Xining (CN); Lixin Wei, Xining (CN); and Chen Chen, Xining (CN)
Assigned to Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining (CN)
Filed by Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining (CN)
Filed on Aug. 7, 2020, as Appl. No. 16/987,800.
Claims priority of application No. 202010206060.4 (CN), filed on Mar. 23, 2020.
Prior Publication US 2021/0290588 A1, Sep. 23, 2021
Int. Cl. A61K 31/305 (2006.01); A61K 31/4406 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/305 (2013.01) [A61K 31/4406 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 9/0019 (2013.01); A61K 9/14 (2013.01); A61K 9/48 (2013.01)] 12 Claims
 
1. A medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), comprising gTso thal and pharmaceutically acceptable excipients.